Pharmaceutical News RSS Feed - Pharmaceutical News

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo). [More]

Study show that silymarin may be a useful treatment for NASH

Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH). [More]
Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes. [More]
Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India. [More]
Several drugs could lead to new MS treatment options

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity. [More]
ADCs based on alpha-amanatin may help treat colorectal cancer

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited. [More]

Capsaicin has beneficial effects on liver damage, study reveals

Results revealed today at the International Liver Congress 2015 show that the daily consumption of capsaicin, the active compound of chilli peppers, was found to have beneficial effects on liver damage. [More]

Baclofen has positive impact on alcohol consumption in patients with ALD

Results revealed today at The International Liver Congress 2015, show that in patients with alcohol-induced liver disease (ALD), Baclofen has a positive impact on alcohol consumption and overall measures of liver function and harm. [More]
Rising shortages of key antibiotics raise serious concerns about effects on patient care

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Diseases and available online. The trends raise serious concerns about the effects on patient care, particularly for infections without effective alternative treatment options. [More]
Purdue University study sheds light on how decitabine drug reverses cell damage

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment. [More]
Chemists working to develop 'greener' processes for discovering, developing medicines

Chemists working to develop 'greener' processes for discovering, developing medicines

Chemists funded by NIH's National Institute of General Medical Sciences are working to develop "greener" processes for discovering, developing and manufacturing medicines and other molecules with therapeutic potential, as well as compounds used in biomedical research. [More]
Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. [More]
Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Researchers at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health found that a botanical formula for breast health inhibited the growth of estrogen receptor-positive (ER+) human breast cancer cells. More importantly, the researchers also found that the formula enhanced the anti-cancer benefits of the drug tamoxifen in the treatment of breast cancer. [More]
New treatment shows promise in easing symptoms of Parkinson's disease

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise. [More]
Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015. [More]
Study finds no association between MMR vaccine and increased risk of autism

Study finds no association between MMR vaccine and increased risk of autism

In a study that included approximately 95,000 children with older siblings, receipt of the measles-mumps-rubella (MMR) vaccine was not associated with an increased risk of autism spectrum disorders (ASD), regardless of whether older siblings had ASD, findings that indicate no harmful association between receipt of MMR vaccine and ASD even among children already at higher risk for ASD, according to a study in the April 21 issue of JAMA, a theme issue on child health. [More]
Female liver cells become more susceptible to adverse effects of drugs, study finds

Female liver cells become more susceptible to adverse effects of drugs, study finds

Female liver cells, and in particular those in menopaused women, are more susceptible to adverse effects of drugs than their male counterparts, according to new research carried out by the JRC. It is well known that women are more vulnerable when it comes to drug-induced liver effects, but it's the first time it has been shown that there are differences at cellular level. [More]
Oral insulin could help prevent type 1 diabetes in high-risk children

Oral insulin could help prevent type 1 diabetes in high-risk children

Children at risk for type 1 diabetes, who were given daily doses of oral insulin, developed a protective immune response to the disease that researchers with the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Campus say could possibly lay the groundwork for a vaccine against the chronic illness. [More]
New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins. [More]
Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. [More]
Advertisement
Advertisement